Selected article for: "long process and vaccine development"
Author: Gallo, Oreste; Locatello, Luca Giovanni; Mazzoni, Alessio; Novelli, Luca; Annunziato, Francesco
Title: The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection
  • Cord-id: cb3xluji
  • Document date: 2020_11_26
    • ID: cb3xluji
    Snippet: The novel coronavirus SARS-CoV-2 enters into the human body mainly through the ACE2 + TMPRSS2+ nasal epithelial cells. The initial host response to this pathogen occurs in a peculiar immune microenvironment that, starting from the Nasopharynx-Associated Lymphoid Tissue (NALT) system, is the product of a long evolutionary process that is aimed to first recognize exogenous airborne agents. In the present work, we want to critically review the latest molecular and cellular findings on the mucosal r
    Document: The novel coronavirus SARS-CoV-2 enters into the human body mainly through the ACE2 + TMPRSS2+ nasal epithelial cells. The initial host response to this pathogen occurs in a peculiar immune microenvironment that, starting from the Nasopharynx-Associated Lymphoid Tissue (NALT) system, is the product of a long evolutionary process that is aimed to first recognize exogenous airborne agents. In the present work, we want to critically review the latest molecular and cellular findings on the mucosal response to SARS-CoV-2 in the nasal cavity and in NALT, and to analyze its impact in the subsequent course of COVID-19. Finally, we want to explore the possibility that the regulation of the systemic inflammatory network against the virus can be modulated starting from the initial phases of the nasal and nasopharyngeal response and this may have several clinical and epidemiological implications starting from a mucosal vaccine development.

    Search related documents:
    Co phrase search for related documents
    • ab individual and acute respiratory sars syndrome: 1, 2
    • activation marker and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • activation marker and acute respiratory sars syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • activation replication and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • activation replication and acute respiratory sars syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • activation status and acute lung injury: 1, 2
    • activation status and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • activation status and acute respiratory sars syndrome: 1, 2
    • actual infection and acute respiratory: 1, 2, 3, 4, 5, 6
    • actual infection and acute respiratory sars syndrome: 1, 2, 3, 4